The stock price of AIkido Pharma Inc. (NASDAQ: AIKI) soared more than 29% in the after-hours session last night after the company revealed positive results from its sponsored Artificial Intelligence/Machine Learning Research program on patients suffering from Pancreatic Cancer.
In the US, pancreatic ductal adenocarcinoma is the third leading cancer-related cause of death. PDA is on the rise, as it is significantly associated with obesity, smoking, and diabetes. A significant obstacle to PDA treatment is that the majority of diagnoses are made late in disease progression. The most effective therapeutic strategy is surgical resection, but it is not curative and is restricted to early-stage diagnosis. While clinical trials have improved the five-year survival rate to 9%, less than 20% of patients survive for a year despite decades of research.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
- 3 Best Telehealth Stocks to Watch For in 2021
- FAANG Stocks: Which 3 stocks are the best to Invest in 2021
It is imperative to develop robust, systematic screening to identify novel, effective PDA therapeutics for the early stages of the disease and after successful surgical resection to delay and prevent relapse. It is the strategy of AIkido to identify better therapeutics by screening drugs in primary cell culture then validating them in a mouse model of early disease progression.